Five years ago, you had $1,000 to invest and two famous American industrial names to choose from. Boeing (NYSE: BA) looked like the safer bet: a century-old aerospace giant, a dividend payer, a ...

Coherent (COHR), EchoStar (SATS), and Vertiv (VRT) were all added to the index, and today — Monday, March 9, 2026 — is their ...

Dow (DOW) trades at $33.28 with RBC target of $40 and 43.97% YTD gain, while LyondellBasell (LYB) trades at $67.11 with RBC target of $82 and 56.84% YTD gain. Geopolitical disruption in Iran is ...

Municipal bonds are often marketed as the safe, tax efficient corner of fixed income. In many cases, that reputation is deserved. Most municipal bonds are investment grade and backed by relatively ...

XRP dropped from $2.40 to $1.11 as the Iran conflict hit crypto markets harder than any ETF or Ripple partnership in 2026. Here's what's next.

Wall Street is turning more constructive on infrastructure-linked names, and two fresh analyst calls this week make the case ...

Wall Street is sending two distinct signals on consumer-facing stocks this week. Grocery Outlet is firmly in the bearish camp, with analysts cutting targets and flagging structural recovery ...

Across three distinct global consumer markets, fresh analyst coverage is drawing a clear map of where institutional conviction sits heading into mid-2026. The signals are mixed: one bullish upgrade, ...

Analyst sentiment on two small-cap aerospace names shifted this week, with Truist upgrading Redwire and Canaccord reaffirming its Buy on Bridger Aerospace despite a price target trim. Both calls point ...

GameStop (GME) stock is up more than 20% year-to-date in 2026, standing out as the winner among major meme stocks, fueled by short-squeeze speculation and buyout chatter surrounding CEO Ryan Cohen. In ...

Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals ...

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 ...